Victory Capital Management Inc. Makes New $51,000 Investment in Ocugen, Inc. (NASDAQ:OCGN)

Victory Capital Management Inc. purchased a new stake in Ocugen, Inc. (NASDAQ:OCGN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 32,642 shares of the company’s stock, valued at approximately $51,000.

A number of other institutional investors have also recently modified their holdings of the business. David J Yvars Group acquired a new stake in Ocugen in the first quarter valued at $35,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Ocugen in the second quarter valued at about $35,000. Headlands Technologies LLC purchased a new stake in Ocugen during the first quarter worth about $66,000. Tidal Investments LLC acquired a new position in Ocugen during the first quarter worth about $108,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Ocugen in the first quarter valued at about $132,000. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

Ocugen Price Performance

OCGN stock opened at $0.98 on Wednesday. The firm has a 50 day moving average of $1.31 and a 200-day moving average of $1.46. The company has a market cap of $251.23 million, a price-to-earnings ratio of -3.90 and a beta of 3.69. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09. Ocugen, Inc. has a 12-month low of $0.35 and a 12-month high of $2.11.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $1.14 million for the quarter. During the same period in the previous year, the company posted ($0.10) earnings per share. As a group, equities analysts expect that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.